Leukemia

Leukemia is a group of blood cancers that affect white blood cells, with approximately 475,000 new cases diagnosed worldwide each year. The disease develops in the bone marrow - the spongy tissue inside bones where blood cells are made - when genetic mutations cause blood cells to grow and divide abnormally. These abnormal cells accumulate in the bone marrow and bloodstream, crowding out healthy blood cells and impairing the body's ability to fight infections, carry oxygen, and control bleeding. Leukemia is classified into four main types based on how quickly it progresses (acute versus chronic) and which type of white blood cell is affected (lymphoid versus myeloid). Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, while chronic lymphocytic leukemia (CLL) typically affects older adults. Acute myeloid leukemia (AML) can occur at any age, and chronic myeloid leukemia (CML) is most common in middle-aged adults. Each type has distinct genetic characteristics, growth patterns, and treatment responses. Symptoms often include fatigue, frequent infections, easy bruising or bleeding, fever, night sweats, and swollen lymph nodes, though some chronic forms develop slowly with few early symptoms.

Treatment varies dramatically depending on leukemia type and has advanced substantially over recent decades. Childhood ALL, once nearly always fatal, now has cure rates exceeding 90% using combination chemotherapy protocols refined over years of research. CML was transformed by targeted drugs called tyrosine kinase inhibitors (TKIs), starting with imatinib (Gleevec), which converted a once-fatal disease into a manageable chronic condition for most patients. AML treatment typically involves intensive chemotherapy, often followed by stem cell transplantation for younger patients or those at high risk of relapse. CLL is often monitored without immediate treatment in early stages (watch-and-wait approach), with therapy starting when disease becomes active; newer targeted drugs like venetoclax and BTK inhibitors have largely replaced chemotherapy as first-line treatment. CAR-T cell therapy - where a patient's immune cells are engineered to attack cancer - has been approved for certain relapsed ALL and large B-cell lymphomas, representing a major immunotherapy breakthrough. Stem cell transplantation from donors offers potential cure for some leukemia types but carries significant risks including graft-versus-host disease. Supportive care including antibiotics, blood transfusions, and growth factors helps manage treatment side effects and complications. Treatment intensity and duration vary widely, from oral medications taken indefinitely for chronic leukemias to months of intensive chemotherapy and hospitalization for acute forms.

AML in older adults remains particularly challenging, as intensive chemotherapy is often poorly tolerated and cure rates are significantly lower than in younger patients, creating need for effective but less toxic treatment options. Relapsed or refractory disease - when leukemia returns after treatment or doesn't respond initially - presents difficult situations across all types, with fewer effective options and often requiring experimental approaches. Stem cell transplant complications, particularly graft-versus-host disease where donor immune cells attack the recipient's body, can be severe and chronic, affecting quality of life for years. The intensity of treatment required for acute leukemias, especially in children, can cause long-term effects including growth problems, learning difficulties, heart damage, and secondary cancers that appear years or decades later. Better methods to predict which patients will respond to specific treatments would enable more personalized therapy selection and help identify who needs intensified treatment versus who can safely receive less. Detecting minimal residual disease - tiny amounts of leukemia remaining after treatment that can't be seen under a microscope but may cause relapse - requires sensitive testing that isn't universally available. Some leukemia subtypes defined by specific genetic mutations still lack targeted therapies that address their underlying drivers.

Multiple new targeted therapies for AML are in Phase 3 trials, including next-generation FLT3 inhibitors for FLT3-mutated leukemia and menin inhibitors for leukemias with specific genetic rearrangements. Bispecific antibodies that simultaneously bind leukemia cells and T cells are showing strong results in trials for ALL and other types, with blinatumomab already approved and newer versions in testing. Next-generation CAR-T approaches addressing limitations of current therapies - including longer-lasting cells, off-the-shelf products that don't require manufacturing from each patient's cells, and CAR-T targeting different leukemia markers - are in advanced trials. Novel drug combinations pairing targeted therapies with chemotherapy or with each other are being evaluated to improve response rates while potentially reducing treatment intensity. For older AML patients, trials are testing less intensive regimens combining targeted drugs like venetoclax with lower-dose chemotherapy or hypomethylating agents, showing promising response rates with better tolerability. New maintenance therapies designed to prevent relapse after initial treatment are in trials for multiple leukemia types. Oral chemotherapy formulations and new drug delivery methods aim to reduce hospital time and improve quality of life during treatment.

Universal CAR-T cells that can be manufactured once and used for multiple patients (rather than custom-made for each person) are being developed to make this powerful therapy faster to access and potentially less expensive. CRISPR gene editing is being explored to create more powerful CAR-T cells, eliminate leukemia-causing mutations, or enhance the immune system's natural cancer-fighting abilities. Scientists are identifying new targets on leukemia cells and developing drugs to attack them, including approaches targeting leukemia stem cells - the small population thought responsible for disease recurrence. Researchers are investigating how the bone marrow microenvironment - the surrounding cells, blood vessels, and chemical signals - protects leukemia cells from treatment, with drugs in development to disrupt this protective niche. Artificial intelligence is being applied to predict which patients will respond to specific treatments based on genetic profiles, treatment history, and clinical characteristics. Liquid biopsy technologies detecting leukemia DNA in blood are being refined for earlier relapse detection and real-time treatment monitoring. Scientists are exploring whether gut bacteria influence treatment response and whether modifying the microbiome could improve outcomes, particularly for stem cell transplant recipients. Researchers are developing therapeutic cancer vaccines to stimulate immune responses against leukemia-specific mutations. New techniques to reduce transplant toxicity while maintaining the beneficial graft-versus-leukemia effect are in development. Drugs that reverse epigenetic changes - alterations in how genes are turned on or off - are being studied as ways to normalize leukemia cell behavior without killing them.